Objective: The impact of hot flashes on sleep is of great clinical interest, but results are inconsistent, especially when both hot flashes and sleep are measured objectively. Using objective and subjective measurements, we examined the impact of hot flashes on sleep by inducing hot flashes with a gonadotropin-releasing hormone agonist.
P erimenopausal and early postmenopausal women report experiencing worse sleep quality more commonly than do premenopausal women of similar age. 1, 2 Although poor sleep quality might be expected as a direct result of hot flashes, data addressing this issue are inconsistent ( Table 1) . When both hot flashes and sleep are reported subjectively, hot flashes are consistently linked to poor sleep quality. 1<4,6<9 In contrast, reports on the relationship between recorded hot flashes and reported sleep quality are much less consistent, 4, 5, 10 as are studies examining the association of reported and objectively recorded (ie, skin conductance monitor) hot flashes with recorded sleep (polysomnography [PSG] or actigraphy). Findings across studies of recorded sleep show increased wakefulness and reduced sleep efficiency in some, 4,9,12<15 but not all, 5, 8, 11, 16 reports.
Unlike in laboratory settings, 17 there is discrepancy between reported and recorded measures of hot flashes in ambulatory settings 10,17<19 which occurs because psychological factors influence subjective reporting 19 and recall of nocturnal events varies. 18 Although both underreporting and overreporting of daytime hot flashes relative to objective assessments are seen, 18, 19 nighttime hot flashes are consistently underreported relative to objective measures. 10, 18 Perception of sleep quality and recorded sleep are also poorly correlated. 20<22 Thus, although hot flash and sleep associations might be expected to differ, depending on the way in which these core menopause-related symptoms are measured, only one study 4 has examined these associations using both objective and subjective measures of hot flashes and sleep. Results of this study 4 show that both reported and recorded hot flash measures were associated with both reported and recorded sleep measures. Although this study is important because it is the only study to measure both hot flashes and sleep concurrently using subjective and objective methods, its cross-sectional design does not allow for causal inference.
Hot flashes are linked with reduced quality of life in midlife women 23 either directly because hot flashes cause daytime discomfort, or indirectly, through their effects on sleep 1,2,6<8 and mood, 24<27 each of which independently contributes to poor quality of life. 23, 28 Understanding the specific causal contribution of hot flashes to the development of poor sleep quality requires precise information on the temporal association between symptoms. The observational and primarily cross-sectional design of previous studies prevents causal inference about the specific impact of hot flashes on sleep quality, thereby limiting our ability to devise clinical strategies to treat these commonly co-occurring symptoms and improve quality of life.
We used a gonadotropin-releasing hormone agonist (GnRHa) that induces hypoestrogenism and mimics hormonal changes in the menopausal transition to isolate the specific effect of newonset hot flashes on sleep quality. Hot flashes are induced rapidly on GnRHa in approximately two thirds of women, 29<33 providing a natural control group of women who undergo the same hormone changes but who do not develop hot flashes. We compared within-woman changes in each sleep parameter from before initiation of GnRHa to 1 month after initiation of GnRHa between those who developed and those who did not develop new-onset hot flashes, as recorded objectively and reported subjectively. We secondarily examined the effect of hot flashes on quality of life using the same approach.
METHODS

Twenty premenopausal healthy volunteers received one
open-label intramuscular injection of the depot GnRHa leuprolide 3.75 mg/day and were followed for 1 month to determine whether they developed hot flashes, at which time posttreatment assessments were completed. Pretreatment and posttreatment measures included sleep quality and quality-oflife questionnaires, 24-hour objective recording of hot flashes, two nights of actigraphic recording of sleep, and continuous reporting of hot flashes on a daily diary throughout the study period. Serum estradiol was measured weekly on GnRHa to confirm that ovarian function was suppressed and that differences in symptom response were not explained by differences in estradiol levels.
Study participants
Healthy premenopausal women aged 18 to 45 years with monthly menstrual cycles and without hot flashes, sleep disorders, depression, or other psychiatric illnesses were enrolled in the study. The absence of hot flashes at baseline was established both subjectively (using a 7-d hot flash diary) and objectively (using a sternal skin conductance monitor for 24 h; Biolog Ambulatory Recorder; UFI, Morro Bay, CA). Participants were carefully screened to select healthy women with regular menstrual cycles and evidence of ovulation (midluteal serum progesterone 93 ng/dL). Women with major depression and significant depressive symptoms were excluded using a standardized psychiatric diagnosis instrument (Patient Health Questionnaire-9). 34 Eligible women were also required to have a score of 16 or lower on the clinician-rated Montgomery-Åsberg Depression Rating Scale (MADRS) 35, 36 (a threshold suggesting the absence of clinically relevant depressive symptoms) 37 and to have no previous psychotic symptoms, suicide attempt, or diagnosis of bipolar disorder, psychosis, anorexia nervosa, or alcohol/substance use disorders.
Other exclusion criteria were as follows: pregnancy; lactation; abnormal prolactin level, thyroid function, liver function, or renal function; primary sleep disorders (sleep apnea, periodic limb movement syndrome, and narcolepsy); and use of centrally active medications (eg, antidepressants, benzodiazepines, and corticosteroids) or medications known to suppress hot flashes (eg, birth control preparations, serotonergic agents, and gabapentin).
Study procedures
Participants received one open-label intramuscular injection of the depot GnRHa leuprolide 3.75 mg/day during the midluteal phase of their menstrual cycle to rapidly induce hypoestrogenism 38<40 and to maintain ovarian suppression for a 1-month period. 31, 32, 41 Serum estradiol, estrone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) were obtained immediately before GnRHa therapy and after 1, 2, and 4 weeks on GnRHa therapy.
After GnRHa administration, participants were monitored closely for a 1-month period to determine the onset of hot flashes using daily diaries and a 24-hour skin conductance monitoring completed at the end of the study. The Biolog monitor is used widely and has good reliability and validity. 42 Consistent with standard procedures, recorded hot flashes were defined as an increase in sternal skin conductance of 2 Kmho or higher during a 30-second period using a 20-second lockout period. 43 Sleep patterns were recorded for two consecutive nights in each participant's home environment using the Actiwatch-Score (Mini Mitter Co. Inc., Bend, OR). Actigraphy data were used to measure sleep efficiency (percentage of time spent asleep between bedtime and wake-up time), wake time after sleep onset (WASO), and sleep onset latency (in minutes) before GnRHa therapy and after 1 month on GnRHa. An awake state was defined for each 30-second epoch when the total activity count was greater than a sensitivity threshold of 80. Subjective sleep quality was documented using the widely used Pittsburgh Sleep Quality Index (PSQI; range of 0-21, with higher scores indicating poorer quality sleep). 44 Quality of life was assessed with the Menopause-Specific Quality of Life Questionnaire (MENQOL), which measures four quality-of-life domains (vasomotor, psychosocial, physical, and sexual) over the past month that are averaged to generate the overall MENQOL score. 45 Daytime sleepiness and depressive symptomsVtwo domains of well-being commonly affected by hot flashes and sleep qualityVwere also measured using the Epworth Sleepiness Scale (ESS; range of 0-24, with higher scores indicating more sleepiness), 46 the self-reported Beck Depression Inventory (BDI; range of 0-63, with higher scores indicating more depressive symptoms), 47 and the clinician-rated MADRS (range of 0-60, with higher scores indicating more depressive symptoms). 35, 36 For safety monitoring, participants were contacted by telephone 2 and 3 months after receiving GnRHa to confirm that menses had resumed, that hot flashes had not subsequently developed, and, where previously present, that hot flashes had resolved. All participants provided a written informed consent form for study procedures, which were approved by the Partners HealthCare Institutional Review Boards.
Hormone assays
Estradiol and estrone were measured using liquid chromatographyYtandem mass spectrometry (Mayo Clinic, Rochester, MN) 48, 49 to achieve accuracy and precision in the low range seen on endocrine therapy. The interassay coefficient of variation for estradiol and estrone in the low range studied was 8.6% and 8.7%, respectively. 48 The lower level of detectability for estradiol was 10 pg/mL. Serum LH and FSH levels were measured in the Massachusetts General Hospital Reproductive Endocrine Laboratory using a two-site monoclonal nonisotopic system according to the manufacturer's directions (Axsym; Abbott Laboratories, Abbott Park, IL), as previously described. 50, 51 LH and FSH are expressed in international units per liter as equivalents of the Second International Pituitary Standard (80/552 and 92/510). The interassay coefficients of variation for LH are 5.3%, 5.5%, and 7.4% for quality control sera containing 5.6, 26.2, and 69.0 IU/L, respectively. The interassay coefficients of variation for FSH are 5.2%, 4.6%, and 5.5% for quality control sera containing 7.4, 15.6, and 42.0 IU/L, respectively.
Data analysis
Analyses were conducted first using an objective hot flash classification and separately using subjective hot flash measurements. Baseline characteristics and serum levels of reproductive hormone at each time point were compared between women with and women without hot flashes, using Fisher's exact tests for categorical variables and nonparametric Wilcoxon rank sum test for continuous variables. For the purpose of analysis, serum estradiol levels below the level of detectability were set to 5 pg/mL (the midpoint between 0 and the lower level of detectability).
Analyses comparing changes in recorded and reported sleep parameters were conducted using nonparametric Wilcoxon rank sum test. For each recorded sleep measure (sleep efficiency, WASO, and sleep onset latency), pretreatment and posttreatment values were calculated using the average from the two actigraphic studies conducted at each time point. The association of hot flash frequency with each sleep and quality-of-life outcome was estimated using Spearman correlations. Because of differences in serum estradiol on week 2 between hot flash groups, ordinal regression models using quartile ranking for sleep endpoints were used to adjust for the baseline sleep measure and the change in estradiol. The same approaches were used to analyze the effect of hot flashes on quality-of-life measures. Analyses were conducted using STATA software (STATA, College Station, TX) and SAS version 9.2 (SAS, Cary, NC). Statistical significance was established using a twosided > of 0.05.
RESULTS
Study participants
After 1 month on GnRHa therapy, new-onset hot flashes were reported by 14 (70%) participants, beginning after a mean (SD) of 8.4 (2.0) days on leuprolide. Hot flashes were recorded objectively in 14 (70%) participants. Among women with hot flashes, the median (interquartile range [IQR]) number of hot flashes reported per day during the 1-month period was 2.5 (1.3 to 5.1), and the median (IQR) number of hot flashes recorded during the 24-hour monitoring period was 5.5 (2.0 to 9.1). There was 80% concordance between the number of women reporting hot flashes and the number of women whose hot flashes were recorded, with hot flashes recorded in 12 (85.7%) of those who reported hot flashes and in 2 (33.3%) of those who did not report hot flashes. Among those with hot flashes, the median (IQR) number of hot flashes reported at night was 1.0 (0.6 to 1.9), and the median (IQR) number of hot flashes recorded during the night was 2.2 (0.8 to 3.4).
For all participants, the mean (SD) age was 30.6 (8.9) years, the mean (SD) body mass index was 27.1 (4.6) kg/m 2 , and half were African American or Hispanic. There were no statistically significant differences in baseline clinical characteristics between hot flash groups, regardless of whether hot flashes were recorded (data not shown) or reported (Table 2) , except for a trend association between age and reported hot flashes (P = 0.07). However, analyses were not adjusted for age because age did not correlate with any sleep or quality-of-life endpoints. 52 Baseline measures of reported sleep quality, recorded sleep patterns, quality of life, daytime sleepiness, and depressive symptoms did not differ between groups, regardless of whether hot flashes were reported ( 
Effects of GnRHa on reproductive hormones
LH and FSH levels were rapidly suppressed on GnRHa (Fig. 1C, D) , consistent with the limited gonadotropin flare expected with midluteal GnRHa administration. 38<40 Serum levels of reproductive hormones (estradiol, estrone, LH, and FSH) did not differ between hot flash groups, regardless of whether subjective (Fig. 1 , A-D) or objective hot flash categorizations (data not shown) were used. The only exception was estradiol level on week 2 (those reporting hot flashes vs those not reporting hot flashes: median, 5.0 vs 8.5 pg/mL, P = 0.03; Fig. 1A ). Within 1 month on GnRHa (Fig. 1A) , all women had serum estradiol levels lower than 15 pg/mL (those with hot flashes vs those without hot flashes: median [IQR], 6.5 [6 to 11.5] vs 11 [8 to 12] pg/mL, P = 0.26).
Effects of recorded hot flashes on recorded sleep patterns, reported sleep quality, and quality of life
Based on recorded hot flashes ( Fig. 2 , Table 3 ), women who developed hot flashes had worsening of recorded sleep efficiency, as indicated by a median (IQR) reduction in sleep efficiency of 2.6% (0.9% to 10.2%), whereas women who did not develop recorded hot flashes had a median (IQR) increase/ improvement in sleep efficiency of 4.2% (0.8% to 7.5%). Therefore, the difference between medians in the change in sleep efficiency was 6.8% between groups (P = 0.005). The within-woman change in sleep efficiency between hot flash groups remained statistically significant after adjusting for changes in estradiol levels on GnRHa (P = 0.01).
There were no statistically significant differences between hot flash groups in the change in sleep onset latency or WASO from baseline to 1 month on GnRHa. However, women with recorded hot flashes spent more time awake after sleep onset (median, 29.0 vs 15.5 min, P = 0.02) and had longer sleep onset latency (median, 24.5 vs 10.3 min, P = 0.05) at the end of the study. The number of recorded hot flashes correlated significantly with the magnitude of the reduction in sleep efficiency (r s = 0.76, P = 0.0001; Table 3 ).
Within-woman changes in PSQI scores did not differ between recorded hot flash groups. There were no statistically significant effects of recorded hot flashes on quality of life (MENQOL), sleepiness (ESS), or mood (MADRS and BDI), except for the MENQOL vasomotor domain (P = 0.02).
Analyses of changes in recorded sleep efficiency scores were similar when the subgroup of women who had both subjective and objective hot flashes (n = 12) was compared with the group of women (n = 4) who had neither (P = 0.01).
Effects of reported hot flashes on recorded sleep patterns, reported sleep quality, and quality of life
There were no effects of reported hot flashes on recorded sleep patterns when hot flash groups were defined subjectively, although an increasing number of reported hot flashes correlated with a greater reduction in sleep efficiency (r s = 0.47, P = 0.04; Table 3 ). PSQI scores increased more in women who reported hot flashes than in those who did not report hot flashes: median (IQR) increase, 2.5 (1.0 to 4.0) versus 1.0 (0-1.0), P = 0.03 ( Fig. 3 , Table 3 ). Adjusting for changes in serum estradiol did not alter the effect of reported hot flashes on within-woman change in PSQI scores (P = 0.02). The number of hot flashes reported correlated with the extent of worsening in sleep quality, as measured by an increase in PSQI (r s = 0.53, P = 0.02). PSQI scores increased by three points or more in 50% of women with hot flashes versus 0% of women without hot flashes (P = 0.04), suggesting a meaningful change in perceived sleep quality among most women who reported developing hot flashes. 53 Quality of life was reduced in women who reported hot flashes, but not in those who did not report hot flashes (Fig. 4 , Table 3 ), as evidenced by an increase in overall MENQOL scores in only those with hot flashes: median (IQR) increase, 1.1 (0.5 to 1.8) versus 0 (0.1 to 0.1), P G 0.001. The MENQOL domains that showed a significant change from baseline to 1 month on GnRHa between reported hot flash groups were the psychological subscore (P = 0.04) and the vasomotor subscore (P G 0.001), and there was a statistical trend toward a greater reduction in quality of life in those who reported hot flashes for the physical (P = 0.06) and sexual (P = 0.09) subscores. The number of hot flashes reported correlated with the amount of worsening in quality of life (increase in overall MENQOL score: r s = 0.82, P G 0.001).
Reduction in quality of life correlated with worsening in perceived sleep quality on the PSQI (r s = 0.57, P = 0.01), but not with changes in recorded sleep efficiency. However, the association between hot flashes and quality of life remained strong after adjusting for PSQI scores (P = 0.02). Worsening of quality of life on MENQOL also correlated with an increase in depressive symptoms on the MADRS (r s = 0.72, P G 0.001) and the BDI (r s = 0.72, P G 0.001), but not in sleepiness on the ESS (r s = 0.10, P = 0.73). Although within-woman changes in levels of depressive symptoms and sleepiness did not differ between subjective hot flash groups, women who reported developing hot flashes had higher levels of depressive symptoms after 1 month on GnRHa than those who did not develop hot flashes on the BDI (median, 2.0 vs 0, P = 0.04) and on the MADRS (median, 3.5 vs 1.0, P = 0.07, statistical trend). As evidence of a meaningful change in depressive symptoms, BDI scores increased by four points or more in 28.6% of women who developed hot flashes, and MADRS scores increased by five points or more in 35.7% of women who developed hot flashes (regardless of whether they were reported or recorded) and in 0% of those who did not develop hot flashes, but these differences did not reach statistical significance.
Analyses of changes in the PSQI and of quality of life were similar when the subgroup of 12 women with reported and recorded hot flashes was compared with the 4 women with neither (change in PSQI, P = 0.07; change in overall MENQOL, P = 0.005).
Adverse event monitoring
The study intervention was well tolerated. Aside from the expected adverse effects of hot flashes, reduced sleep quality, and depressive symptoms, the most common adverse effects occurring in more than 5% of participants were fatigue (n = 3), headache (n = 2), upper respiratory tract infection (n = 2), acne (n = 1), bloating (n = 1), irritability (n = 1), malodorous urine (n = 1), increased libido (n = 1), and edema (n = 1). No participant withdrew because of adverse effects. Within 3 months of GnRHa administration, hot flashes resolved, and all women resumed their menstrual cycles. No one developed hot flashes after the first month on GnRHa.
Onset of clinically significant depressive symptoms was rare. Only one participant (5%) who developed hot flashes had a MADRS score on GnRHa that exceeded 15, suggesting clinically significant depression. Her depressive symptoms manifested 1 month after receiving GnRHa (MADRS score, 28) and resolved spontaneously within 2 months.
DISCUSSION
This study provides important evidence of a causal relationship between hot flashes and reduced sleep quality from a controlled experimental paradigm. Our results indicate that women with recorded hot flashes are more likely to have deterioration of recorded sleep, but they do not report a reduction in sleep quality or quality of life. In contrast, those who report hot flashes are more likely to report a reduction in sleep quality, but they do not have detectable changes in recorded sleep patterns, except when reported hot flashes are more frequent. Reported hot flashes and worsening of perceived sleep quality were associated with reduction in quality of life, although a similar relationship was not seen with recorded hot flashes and quality of life. Because changes in estradiol and gonadotropins were similar for those developing hot flashes and those not developing hot flashes, between-group differences in sleep parameters do not seem to be attributable to a divergent hormone response to GnRHa. By inducing hot flashes in women without sleep disturbances at baseline and by measuring hot flashes and sleep using both objective and subjective methodologies, findings from this small but rigorously controlled study provide evidence that hot flashes impair sleep.
It is not surprising that recorded hot flashes result in deterioration of recorded sleep efficiency but do not affect reported sleep quality because not all recorded nocturnal hot flashes are perceived or recalled in the morning. 54 We hypothesize that nocturnal hot flashes may not be recalled if they result in only a brief arousal or lightening of sleep stage, as a more sustained awakening may be required for a hot flash to be remembered. 52 If sleep is only minimally disturbed from repeated brief arousals or episodes of sleep stage lightening, recorded sleep efficiency might be reduced, but reported sleep quality may not be impaired. Conversely, reported hot flashes may result in deterioration of perceived sleep quality but may not influence recorded sleep efficiency because only those hot flashes associated with awakenings of sufficient length to generate memory are recalled in the morning. 52 It is notable that the number of reported hot flashes correlated with a greater reduction in sleep efficiency (Table 3) . Therefore, it is only when reported hot flashes are more frequent that recorded sleep is affected.
Given the relatively small number of hot flashes that we and others 12<15 have recorded at night, it is improbable that brief awakenings resulting from recorded hot flashes alone explain the observed reduction in sleep efficiency. We hypothesize that transient increases in core body temperature that precede objective hot flashes 55<57 may also fragment sleep because increases in core temperature are known to induce awakenings. 58 In women with hot flashes, the 1-C core temperature increase that commonly precedes a flash can last for as long as 20 minutes. 56, 57 Such transient yet prolonged temperature increases may fragment sleep enough to reduce sleep efficiency. PSG studies are needed to confirm this hypothesis.
With the inducement of hot flashes, the experimental design of our study advances our understanding of the impact of new-onset hot flashes on sleep, although PSG or more actigraphy nights would provide a stronger method of recording sleep than our current approach. The optimal measurement of hot flashes is a matter of intense debate. 17, 18, 59 It is increasingly clear that reported and recorded hot flashes are not identical, and that although subjective assessment is most important as a therapeutic target, objective measures play an important role in laboratory and sleep-related mechanistic studies. 17, 18 The approach to measuring reported or recorded hot flashes differs in that, whereas diaries can be completed during a protracted period, objective hot flashes are typically recorded for only 1 to 7 days, making assumptions about the stability of this symptom recording over time. These different time frames, together with the discrepancies observed between reported and recorded hot flashes owing to psychological factors and recall of nocturnal events, 10,17<19 may contribute to the differential effects of reported and recorded hot flashes on reported and recorded sleep quality. Our study is one of a few studies 4 that combine measurement approaches for both hot flashes and sleep but provide the advantage of understanding causal relationships because of the experimental design.
Our data further support studies showing that recorded hot flashes are linked to recorded reductions in sleep efficiency. 4, 13, 14 Our work is also consistent with numerous studies showing that reported hot flashes are linked to a reduction in reported sleep quality 1,2,4,6<9 Studies examining the link between recorded hot flashes and reported sleep are mixed, with our data supporting the absence of an association, 10 although differences in study design limit direct comparison. Our findings are consistent with some, 8, 11 but not all, 4, 9 studies showing the absence of an association between reported hot flashes and recorded sleep. Experimental studies of induced hot flashes using PSG to measure sleep would more definitively determine the effects of hot flashes on recorded sleep.
The baseline level of sleep efficiency that we recorded and the magnitude of sleep efficiency reduction after the development of hot flashes are similar to those seen in other studies. 11, 13, 14 Although a 3% median reduction in sleep efficiency among those developing hot flashes is modest, it is notable that pharmacologic interventions for insomnia have been approved by the Food and Drug Association for equally small changes, 60 suggesting that relatively small changes in sleep time can have a meaningful impact on perceived sleep quality in individuals with insomnia. Similar to changes in recorded sleep, the magnitude of change in perceived sleep quality that we observed among those reporting hot flashes (PSQI score increased by Q3 in 50%) is considered a meaningful change in perceived sleep quality. 53 Moreover, our study population was not highly symptomatic, with medians of 2.5 reported hot flashes and 5.5 recorded hot flashes, on average, each day. Because we found that those with more frequent hot flashes had larger deteriorations in sleep efficiency and perceived sleep quality, it is expected that midlife women with more frequent symptoms would also have more marked disruptions of their sleep.
Our data further support that quality of life is reduced in women reporting hot flashes. 23 Although reduced perceived sleep quality correlated with impaired quality of life, sleep disruption alone does not seem to explain the negative impact of hot flashes on quality of life. These findings suggest that mechanisms such as episodic heat intolerance and sweating may be responsible for impaired quality of life in women with hot flashes.
This study uses an experimental model of hot flashes to isolate the effects of new-onset hot flashes on sleep and quality of life. By selecting young premenopausal women for this controlled investigation, we are, by definition, not studying a naturalistic population of midlife perimenopausal and postmenopausal women with hot flashes. Using the younger population eliminates the confounding of age-related sleep changes from our study, but we may have underestimated the effect of hot flashes on sleep because this group of young women with good sleep at baseline may be more resilient to mild sleep per-turbation. One important limitation of this study and other studies 4, 9 is that actigraphy is an indirect objective sleep measure that can underestimate wakefulness during sleep periods. 61 Studies using PSG as the gold standard for objective sleep are needed to more definitively establish the impact of hot flashes on recorded sleep.
Consistent with other experimental studies, 62 this study was small because of cost considerations and the intensity of study procedures. Although analyses of these types of studies must consider chance associations and multiple comparisons, the within-woman subtraction of pretreatment symptom levels from posttreatment symptom levels reduces variability and makes for a more precise estimate of each sleep and qualityof-life measure. The consistency of associationsVrecorded hot flashes versus recorded sleep outcomes, and reported hot flashes versus reported sleep and quality-of-life outcomesV reduces the likelihood that the observed associations were found by chance. This prospective design, using a model of induced hot flashes, also has the important advantage of enabling causal inference about the consequences of hot flashes on well-being. 
CONCLUSIONS
